Autophagy-lysosomal lipid metabolism in adipose tissue during acute and chronic metabolic stress
Description: Adipose tissue (AT) dysfunction is a central driver of obesity-related cardiovascular disease, largely through the release of excess fatty acids that cause systemic lipotoxicity. While AT lipolysis is essential for energy homeostasis, a critical paradox exists: in obesity, the canonical cytosolic pathway (mediated by ATGL) is suppressed, yet overall lipolysis remains elevated. This suggests a critical, alternative pathway is activated to manage lipid overload. Our research targets this alternative mechanism: autophagy-lysosomal lipolysis (lipophagy). We found that core autophagy (Atg5) and lysosomal (LAL) genes are robustly upregulated in obese adipocytes, functioning as a potential compensatory mechanism. My foundational work, supported by a previous AHA Postdoctoral Fellowship (24POST1198554) and published in the Journal of Clinical Investigation (2025), established the non-redundant, critical role of the downstream enzyme LAL in vivo. However, the upstream mechanism delivering lipids to the lysosome (Atg5-dependent lipophagy) remains undefined in mature adipocytes. We hypothesize that Atg5-dependent lipophagy operates as a distinct, parallel pathway to ATGL-mediated lipolysis and is essential for metabolic adaptation. Critically, our new preliminary data support this: adipose-specific Atg5 knockout mice phenocopy the lipolytic defects of A-LAL KO mice, confirming they operate in the same essential axis. This proposal will systematically dissect this hierarchy focusing solely on the adipocyte. We will leverage a unique and powerful genetic toolkit of adipose-specific single and Double Knockout (DKO) mice (A-Atg5, A-LAL, A-ATGL). Aim 1 will define the contribution of each pathway to acute metabolic stress and identify their unique lipidomic signatures. Aim 2 will dissect their roles during chronic stress, focusing on obesity and introducing aging as a novel model to investigate metabolic decline. This study will be the first to definitively define the role of lipophagy in mature adipocytes. By identifying a distinct, druggable pathway (e.g., via autophagy-lysosome modulation), this work addresses the AHA's mission by revealing novel therapeutic targets to treat lipotoxicity and cardiovascular complications, offering a viable alternative to the difficult-to-target canonical pathway.
Funder: American Heart Association
Amount: $231,000
Funding type: fellowship
Funder scheme: Career Development Award
Start date: 2026-04-01
End date: 2029-03-31
Investigator: Yu-Sheng Yeh (lead)
Institution: University of Pittsburgh
Subfield: Cell Biology
Domain: Life Sciences
Funded outputs count: 0
Funder award ID: 26CDA1598076
OpenAlex ID: G5875141380
